A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Michael Friedlander, Tarek Meniawy, Ben Markman, Linda R. Mileshkin, Paul R. Harnett, Michael Millward, Joanne Lundy, Alison E. Freimund, Christie Norris, Song Mu, John Wu, Virginia E. Paton, Lai Wang, Bo Gao

Research output: Contribution to journalAbstract/Meeting Abstractpeer-review

15 Citations (Web of Science)
Original languageEnglish
Number of pages5
JournalJournal of Clinical Oncology
Publication statusPublished - 20 May 2017
Event53rd Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, United States
Duration: 2 Jun 20176 Jun 2017

Cite this